Alnylam's gene-blocker study may help assuage safety worries

09/27/2007 | Bloomberg1

Alnylam Pharmaceutical's latest animal study may ease safety concerns over its experimental drugs derived from RNA interference, the company said. Researchers found that Alnylam's gene-blocking molecules were able to block about 80% of the genes' effects on mice without disturbing a critical cell regulation system.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ